Phase 2 Peripheral Neuropathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with breast cancer (confirmed by tissue testing) at stage I, II, or III
- People whose treatment plan includes a taxane-based chemotherapy course lasting at least 12 weeks, whether given before or after surgery — including combinations with other chemotherapy drugs, anti-HER2 therapies, or immunotherapy drugs
- People aged 18 or older
- People with a general health and activity level that falls within an accepted range for clinical trials (confirm with trial site)
- People whose blood counts, liver function, and kidney function meet minimum levels required by the trial (confirm with trial site for specific values)
- People who have had or currently have another type of cancer, as long as that cancer or its treatment is unlikely to interfere with this trial's results
- People who have previously been diagnosed with diabetes, provided they do not have nerve damage or numbness in their hands or feet
- People who are willing and able to sign a consent form, or who have a legal representative who can do so on their behalf
- People who have not previously received taxane or platinum-based chemotherapy
- Women who could become pregnant must have a negative pregnancy test within 14 days before starting the trial
- People who are able to become pregnant or father a child must agree to use reliable contraception during treatment and for 28 days after the last dose, and male participants must also agree not to donate sperm during this period
Who may not be able to join:
- People who already have a diagnosis of nerve damage or numbness (peripheral neuropathy)
- People who received chemotherapy for their current breast cancer before the planned taxane-based treatment
- People who are currently taking part in another clinical trial involving an investigational drug
- People who are currently using, or have used, antihistamine medications within 2 days before or during the study period
- People who have had an allergic reaction to a drug that is chemically similar to desloratadine
- People with a serious uncontrolled medical condition or other significant health issue that would make participation unsafe
- People who are pregnant or breastfeeding
- People who are currently taking probiotic supplements
- People who regularly use laxatives or enemas
- People who have taken antibiotics within the 4 weeks before registering for the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jesus R Anampa, MD, MS, Montefiore Medical Center
Phone: 7184058505
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in Functional Assessment of Cancer Therapy (FACT)/Gynecologic Oncology Group (GOG)-Neurotoxicity (NTX) Subscale Version 4 (FACT-GOG-NTX) neuropathy score
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.